Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Recruiting · Phase 2 · NCT05003986
Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
At a glance
- Research payments reported, 2025
- $554,494
- U.S. investigators named
- 18
- Sites paid
- 17
- Planned or actual enrollment
- 67
About the trial
- Sponsor
- Travere Therapeutics, Inc.
- Tested
- Sparsentan (drug), Sparsentan (drug), Sparsentan (drug)
- Dates
- Started 2021-08-12; completion 2027-04-12
- Results posted
- Not yet
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
From ClinicalTrials.gov, last updated 2026-05-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Travere Therapeutics, Inc. reported $554,494 in research payments for this study in 2025 (165 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Elaine S. Kamil, M.D. Pediatric Nephrology · Los Angeles, CA
- Caroline A. Gluck, M.D. Pediatric Nephrology · Wilmington, DE
- Ana L. Paredes, M.D. Pediatric Nephrology · South Miami, FL
- Wacharee Seeherunvong, MD Pediatric Nephrology · Miami, FL
- Jennifer Y. Yee, M.D. Pediatric Nephrology · Ann Arbor, MI
- Michelle N. Rheault, M.D. Pediatric Nephrology · Minneapolis, MN
- Tarak Srivastava, MD Pediatric Nephrology · Kansas City, MO
- Rasheed Gbadegesin, M.D. Pediatrics · Durham, NC
- Keisha Gibson, M.D. Pediatric Nephrology · Chapel Hill, NC
- Susan F. Massengill, MD Pediatric Nephrology · Charlotte, NC
- Guillermo Hidalgo, MD Pediatric Nephrology · Neptune, NJ
- Kenneth V. Lieberman, MD Pediatric Nephrology · Hackensack, NJ
- Pamela Singer, M.D. Pediatric Nephrology · New Hyde Park, NY
- Mahmoud Kallash, MD Pediatric Nephrology · Columbus, OH
- Ikuyo Yamaguchi, MD Pediatric Nephrology · Oklahoma City, OK
- Kevin E. Meyers, M.D. Pediatric Nephrology · Philadelphia, PA
- Sahar Siddiqui, MD Pediatric Nephrology · Houston, TX
- Joseph T. Flynn JR., MD Pediatric Nephrology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University $88,573
- Regents of the University of Minnesota $66,398
- Hackensack University Medical Center, NJ $59,709
- Baylor College of Medicine $53,922
- Cedars-Sinai Medical Center, CA $48,422
- University of Michigan Health System, MI $45,555
- Children's Hospital of Philadelphia, PA $42,845
- Seattle Children's Hospital, WA $31,659
- The Children's Mercy Hospital, MO $26,169
- The University of North Carolina at Chapel Hill $20,437
- The Feinstein Institutes for Medical Research $18,650
- Nicklaus Children's Hospital, FL $15,595
- University of Miami $14,753
- The Research Institute at Nationwide Childrens Hospital $10,570
- Carolinas Medical Center-Northeast, NC $5,500
- Nemours Children's Hospital, Delaware, DE $4,986
- Board of Regents of the University Of $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.